A report from MagellanRx focuses on specialty drugs which are covered under the medical, not pharmacy, benefits of health plans.
Read More
Another Mark Farrah Associates report covers enrollment and trends in Medicare Part D plans.
Read More
The Pew Charitable Trusts issues a report on how to use drug payment policies to better manage spending.
Read More
CVS issues its 2016 Drug Trend Report, showing the continued influence of brand, especially specialty brand, drug price increases on overall trend.
Read More
An article in the New England Journal of Medicine explores potential conflicts of interest for patient advocacy groups.
Read More
A blog post at Health Affairs suggests that drug manufacturers don't need US prices to support R & D.
Read More
Prime Therapeutics issues a press release about its drug trend for 2016.
Read More
Express Scripts offers up the first 2016 Drug Trend report, with forecasts for the future to boot.
Read More
A study at the Public Library of Science finds that use of pharmacogenomics in managing drug regimens can help reduce readmissions and ER use.
Read More
A report from the Berkeley Research Group analyzes what proportion of total revenue various parties in the prescription drug manufacturing and distribution chain receive.
Read More
Merck has released showing that it had a net 5.5% unit price increase across all its drugs in 2016. It is acting like it is some kind of a hero for its transparency. This is disgraceful, that increase in far above general inflation and personal income growth. It also makes no sense, because Merck's costs for the drug are undoubtedly going down. So should prices. The drug companies are inevitably going to get what they deserve for avaricious behavior.
http://www.wsj.com/articles/merck-reveals-details-on-u-s-drug-pricing-practices-1485518403Two pieces of research find that while more doctors won't see drug company sales reps, the use of DTC advertising appears to be a fine substitution.
Read More
Research carried by the American Journal of Managed Care suggests that interventions to improve adherence to medication regimens have a near-term payback in overall medical cost savings.
Read More
An article in JAMA discusses why the US has high drug prices and what might be done to lower them.
Read More
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at khroche@healthy-skeptic.com.
Apple Podcasts
Google Podcasts
Spotify
Overcast
PocketCasts
Radio Public
Stitcher
Anchor
RSS - Posts